It was conducted a prospective study with a series of 50 patients treated with PRP one-shot injection in patient affected by Supraspinatus Tendinosis. One independent observer performed clinical and functional evaluations at T0 (recruitment), T1 (one month after the injection), T2 (three months after the last injection) and T3 (six months after the last injection).

Constant Score, The Disabilites of the Arm,Shoulder and Hand Score (DASH) And Visual Analogue Scale (VAS) were administered at each evaluation.

Inclusion Criteria:

• Age > 18 years old;
• Supraspinatus tendinosis detected by MRI.

Exclusion Criteria:

• Supraspinatus rupture;
• Previous shoulder surgery;
• Rotator cuff tears secondary to fracture;
• Hemoglobin <7 g/dL or Platelets < 30,000 microL;
• Active infection;
• Pregnant patients;
• Patients with hematologic and oncologic diseases.

Fifty (50) patients referring to the Orthopaedic and Trauma Unit of the local University Hospital between January 2018 and July 2020 with Supraspinatus tendinosis were prospectively recruited.